IDXGD · Interpace Biosciences, Inc. · Executive Compensation
Market Cap
$178.67M
Shares
27.70M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Robert Gorman | director | Resigned | 2023-12-12 |
| Robert Gorman | Chairman of the Board | Resigned | 2023-12-12 |
| Edward Chan | Class II director | Resigned | 2023-11-16 |
| Christopher McCarthy | Chief Financial Officer | Appointed | 2023-08-02 |
| Christopher McCarthy | Principal Financial Officer | Appointed | 2023-04-25 |